Goldman Sachs initiated coverage of Alignment Healthcare (ALHC) with a Buy rating and $21 price target The managed care industry faces its most significant underwriting downturn in over 15 years, the analyst tells investors in a research note. Goldman recommends increased exposure to Medicare Advantage as it sees a margin recovery phase beginning in 2026. However, the firm does not see the Medicare Advantage recovery playing out uniformly across the group in 2026. The analyst also sees a longer path to cyclical recovery in Medicaid and the healthcare exchange.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALHC:
- Clover Health ‘loses big’ in CMS star ratings, says Leerink
- Alignment Healthcare announces 100% of MA members enrolled in 4+ stars plans
- Alignment Healthcare announces its 2026 product portfolio
- Alignment Healthcare’s Strong Star Ratings and Growth Potential Drive Buy Rating
- Alignment Healthcare falls -6.6%
